Halo Collective Plans to Expand Retail Space after Record Sales

Nov.23.2022
Halo Collective Plans to Expand Retail Space after Record Sales
Halo Collective reports highest sales quarter and plans to expand Budega retail stores, aiming for seven more locations in the US by 2023.

During this quarter, Halo Collective experienced its highest reported sales and continues to plan expansion with the successful opening of its first two Budega retail stores. The opening of the third supermarket store has made significant progress.


After reviewing its current operations, the company is actively seeking additional retail space and licenses in the United States, with a goal of securing up to seven locations by the end of 2023. Retail stores represent a valuable resource for sales and customer data, as they allow for vertical integration and offer a range of cannabis-related products, including food, pre-rolls, e-cigarettes, flowers, tinctures, creams, and more.


The company has successfully acquired three locations in the California area, including Westwood, NoHo, and now Hollywood, and plans to open seven more stores next year. Since its opening in early March of this year, the NoHo store has continued to grow with steady increases in revenue, offering unique promotional events to drive consumer traffic while maintaining a loyal and consistent customer base. In October of last year, the company implemented innovative changes to increase the stores' net profit. All retail locations promote their own products, including the top-selling Budega and Hush flower brands.


Westwood has experienced rapid growth over the past six months, with monthly revenues nearly doubling and peaking in sales in October of last year. Sales in the third quarter increased by 94% compared to the second quarter, and the company anticipates fourth quarter sales in Westwood to be based on October's sales figures. The pharmacy is conveniently located between Westwood and Beverly Hills, adjacent to Santa Monica Boulevard in a high-traffic area. Westwood is also the nearest pharmacy to the tourist areas of Beverly Hills and Century City.


Budega, a retail brand in the California cannabis industry, has established its presence as a prominent player. Following positive initial evaluations, the company is continuing its expansion plans in the region next year. Budega Hollywood, the largest of its three stores, has made significant progress and is projected to generate $15 million in revenue by 2023. The company has hired a renowned contractor to oversee the store's expansion and design, and has approved renderings to move forward with the development.


Regarding Halo Collective


Halo is a company that focuses on the west coast of the United States and vertically integrates its business, covering the entire value chain from seed to sale. The company grows, extracts, manufactures, and distributes high-quality cannabis flowers, pre-rolls, vape carts, edibles, and concentrates. These products are sold under a range of brands, including Hush™, Winberry Farms™, their retail brand Budega™, as well as through a licensing agreement with FlowerShop*. Additionally, Halo has opened two dispensaries under the Budega™ brand in North Hollywood and Hollywood, with plans to open another in Hollywood in 2022.


In the non-THC space, Halo is expanding into the health and wellness categories, including CBD and functional supplements such as brain-boosting nutrition products and non-psychedelic mushrooms. Through a series of acquisitions, Halo offers products in the form of beverages (H2C Beverages), dissolvable strips (Dissolve Medical), capsules (Hushrooms™), and topical supplements (Hatshe), and plans to distribute nationally through a strategic agreement with SWAY Energy.


Halo has successfully acquired and integrated multiple companies, subsequently restructuring to create Akanda Corp. (NASDAQ stock code: AKAN), an international medical cannabis and health company in which Halo is the largest shareholder. Halo has also acquired a series of software development assets including CannPOS, Cannalift, CannaFeels, and discrete sublingual delivery technology Accudab. Halo intends to restructure these entities (including their intellectual property and patent applications) into a subsidiary named Halo Tek Inc. and complete the distribution of Halo Tek Inc. shares to registered shareholders on a date to be determined.


Statement:


This article is compiled from third-party information and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's proficiency, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign issues and stances.


5. The copyright of the compiled information belongs to the original media and authors. If there is infringement, please contact for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
British American Tobacco Japan (BAT Japan) expanded VELO Peach Ice Medium to FamilyMart stores nationwide in Japan from September 7, 2026. The oral tobacco product first launched on July 6 and had previously been sold through VELO's official online store, glo Store Ginza and tobacco retailers. It combines peach flavor with menthol cooling at a Medium strength level and is priced at JPY 360. Japanese tobacco retailers list 15 pouches per pack. The move adds the new SKU to an existing nationwide FamilyMart distribution network for VELO rather than marking the brand's first entry into the convenience-store chain.
Sep.15
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22